文献速递淋巴瘤

维奈克拉联合剂量调整EPOCH-R方案初治侵袭性B细胞淋巴瘤的单臂多中心1期研究

Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
PubMed 文献 · Lancet Haematol · 2021-10-08

该单臂多中心1期研究评估维奈克拉联合剂量调整EPOCH-R初治侵袭性B细胞淋巴瘤的安全性和初步活性。30例患者中最大耐受剂量为800mg×10天,推荐2期剂量为600mg×5天;常见3-4级不良事件为血细胞减少(93%)和发热性中性粒细胞减少(63%)。

要点

  • 维奈克拉联合剂量调整EPOCH-R在推荐2期剂量下安全性可接受。
  • 推荐2期剂量为维奈克拉600mg每日一次×5天。

核心结论

  • 维奈克拉联合剂量调整EPOCH-R在推荐2期剂量下安全性可接受,在高危患者中显示出鼓舞人心的初步活性,值得进一步研究。

研究设计与样本

  • 单臂、多中心1期研究,在美国7个治疗中心开展,共纳入30例初治侵袭性B细胞淋巴瘤患者。

主要发现

  • 最大耐受剂量为维奈克拉800mg每日一次×10天;推荐2期剂量为600mg每日一次×5天。
  • 30例中1例(3%)在800mg剂量第1周期出现剂量限制性毒性(4级血小板减少)。
  • 最常见3-4级不良事件为血细胞减少(28/30,93%),发热性中性粒细胞减少19例(63%)。

关键数值与推荐

  • 推荐2期剂量为维奈克拉600mg每日一次×5天,联合剂量调整EPOCH-R每3周1周期,共6周期。

临床怎么用

  • 该联合方案可作为高危侵袭性B细胞淋巴瘤患者的潜在初治选择,但需关注血细胞减少和感染风险。

局限性

  • 单臂1期研究,样本量小(30例),初步活性结果需进一步随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) is a front-line treatment for patients with aggressive B-cell lymphomas. Bcl-2 is associated with chemoresistance due to BCL2 gene rearrangement or protein overexpression and is antagonised by venetoclax. We aimed to assess the safety of venetoclax with dose-adjusted EPOCH-R as initial therapy in aggressive B-cell lymphoma. METHODS: We conducted a single-arm, phase 1 study across seven treatment centres in the USA. Eligible patients were aged 18-80 years with histologically confirmed, previously untreated diffuse large B-cell lymphoma, transformed indolent non-Hodgkin lymphoma, high-grade B-cell lymphoma with double-hit or not otherwise specified, or primary mediastinal B-cell lymphoma, with Ann Arbor stage II-IV and Eastern Cooperative Oncology Group performance status of 0-2. Participants received six cycles of oral venetoclax 400 mg, 600 mg, or 800 mg once daily for 10 days per cycle with dose-adjusted EPOCH-R (one cycle every 3 weeks; baseline doses were intravenous rituximab 375 mg/m2 on day 1, intravenous etoposide 50 mg/m2 on days 1-4, oral prednisone 60 mg/m2 twice daily on days 1-5, intravenous vincristine 0·4 mg/m2 on days 1-4, intravenous cyclophosphamide 750 mg/m2 on day 5, and intravenous doxorubicin 10 mg/m2 on days 1-4). A subsequent cohort received venetoclax 600 mg once daily for 5 days per cycle. The primary endpoints were the maximum tolerated dose, dose-limiting toxicities, and the recommended phase 2 dose of venetoclax. Analyses were done per protocol. This trial is registered with ClinicalTrials.gov, NCT03036904, and enrolment is now closed. FINDINGS: Between Feb 3, 2017, and June 4, 2019, 34 patients were assessed for eligibility, and 30 were enrolled and received venetoclax with dose-adjusted EPOCH-R. The median patient age was 64·0 years (IQR 51·6-69·4). The maximum tolerated dose was 800 mg for 10 days and the established recommended phase 2 dose was 600 mg for 5 days due to tolerability for treatment duration. One (3%) of 30 patients had a dose-limiting toxicity in cycle one (grade 4 thrombocytopenia with 800 mg dose). The most common grade 3-4 adverse events were cytopenias (28 [93%] of 30 patients); febrile neutropenia occurred in 19 (63%) patients. Grade 3-4 non-haematological adverse events included hypophosphataemia (n=10), hypokalaemia (n=7), and hyperglycaemia (n=5). Serious adverse events included infection (n=7) and gastrointestinal toxicities including abdominal pain (n=3), colonic perforation (n=1), and small intestinal obstruction (n=1). There was one treatment-related death (sepsis). Overall response rate was 96·7% (95% CI 82·8-99·9); 28 (93·3% [77·9-99·2]) of 30 patients had complete response and one (3·3% [0·1-17·2]) had a partial response. INTERPRETATION: Venetoclax with dose-adjusted EPOCH-R showed an acceptable safety profile at the recommended phase 2 dose and had encouraging preliminary activity in this population at high risk of adverse outcomes, and is worthy of further study. The combination is being investigated in Alliance 051701 (NCT03984448). FUNDING: Genentech.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Rutherford SC, Abramson JS, Bartlett NL, et al. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol. 2021. PMID: 34634256. doi:10.1016/S2352-3026(21)00273-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。